The following is a statement provided by PPTA.Â
“Hello Stakeholders,Â
As previously noted, I am writing to inform you of an update to PPTA’s statement regarding coronavirus and the safety of plasma protein therapies. This update provides clarity regarding the safety margins of plasma protein therapies manufactured by PPTA member companies and maintains the main assessment of previous versions: PPTA considers the SARS-CoV-2 outbreak to not be of concern for the safety of plasma protein therapies manufactured by PPTA member companies. PPTA members’ existing manufacturing methods provide significant safety margins against the virus. Translations of the statement (in French, German, Italian, Portuguese, and Spanish) will be available in the coming days.Â
PPTA’s Pathogen Safety Steering Committee, comprised of the plasma industry’s leading experts on global pathogen safety, continues to monitor the situation and will provide additional updates as needed.Â
Please do not hesitate to contact me directly at the Association via email or via telephone (+1-443-458-4669) if you have any questions in the meantime.Â
Mathew Gulick
Director, Global Communications
Plasma Protein Therapeutics Association”Â
